ArticleCase reports in oncology
Are Poly (ADP-Ribose) Polymerase Inhibitors Safe in Paraneoplastic Dermatomyositis due to High-Grade Serous Carcinoma of the Ovary? A Case Report and a Review of the Literature.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dermatomyositis (DM) is a chronic autoimmune disorder characterized by noninfectious inflammation of the muscles and skin [Curr Treat Options Neurol. 2003;5(5):349-56]. An interesting aspect of DM is its correlation with cancer, particularly as paraneoplastic syndrome, in up to 30% of all cases [Int J Mol Sci. 2020;21(6):2178]. There is a notable association with specific cancers, such as lung cancer in men and breast or ovarian cancer (OC) in women. OC is responsible in up to 13.3%-21.4% of DM cases in women. Thus, it is important to explore whether poly (ADP-ribose) polymerase inhibitors (iPARP), a key component of OC maintenance treatment, are safe to use in patients with paraneoplastic DM especially since iPARP could be associated with an immunomodulatory effect with unknown impact on paraneoplastic syndromes. Case Presentation: A 69-year-old patient without significant comorbidities was undergoing dermatological investigations for a persistent skin rash suspect of DM. In her preplanned appointment, bilateral ovarian masses were detected. The skin biopsy confirmed a DM. The DM was associated with an underlying advanced FIGO IIIC high-grade serous ovarian cancer (HGSOC) not amendable to a primary debulking surgery. Following perioperative chemotherapy and a macroscopically complete interval debulking surgery, the patient was to receive iPARP. On immunosuppressive treatment, DM was in near complete remission; thus, the safety of iPARP needed to be reviewed before treatment initiation. Conclusion: This article reports on a case of HGSOC receiving iPARP maintenance following standard of care interval debulking surgery. On this treatment, the patient did not experience DM flair and remains in complete oncological response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.